Dr Francesco Fusco is a Research Associate in the Cambridge Research Methods Hub (CRMH). He received his Pharmacy Degree from “Università degli Studi di Napoli Federico II” and his Master in Clinical Research from “Università degli Studi di Milano”. He was also awarded a PhD in Management of Innovation in Healthcare from the Sant’Anna School of Advanced Studies. Prior to moving to Cambridge, he was a Research Fellow at the Centre for Health Economics of the University of York and a Post-Doctoral Researcher at the Health Economics Research Centre of the University of Oxford.
Francesco was involved in numerous economic evaluations of health interventions, across multiple disease areas, employing simulation and trial-based methods. His research interests lie in generating evidence to support the development as well as the adoption of health technologies, personalised medicine and value of information analysis.
Wolstenholme J*, Fusco F*, Gray A.M., et al. Quality of life in the FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised trials of selective internal radiotherapy for metastatic colorectal cancer. International Journal of Cancer. (in press) *Authors contributed equally
Beard DJ, Davies LJ, Cook JA, et al. The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial. Lancet. 2019 Aug 31;394(10200):746-756. doi: 10.1016/S0140-6736(19)31281-4. Epub 2019 Jul 17.
Fusco F, Campbell H, Barker K. Rehabilitation after resurfacing hip arthroplasty: cost-utility analysis alongside a randomised controlled trial. Clin Rehabil. 2019 Jun;33(6):1003-1014. doi: 10.1177/0269215519827628.
Fusco F, Turchetti G Telerehabilitation after total knee replacement in Italy: cost-effectiveness and cost-utility analysis of a mixed telerehabilitation-standard rehabilitation programme compared with usual care BMJ Open 2016;6:e009964. doi: 10.1136/bmjopen-2015-009964
Gringeri A, Leissinger C, Cortesi PA et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia. 2013 Sep;19(5):736-43. doi: 10.1111/hae.12178.